SEARCH

SEARCH BY CITATION

References

  • 1
    Daughaday WH. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990; 127: 1–4
  • 2
    Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrine Rev 1989; 10: 68–91
  • 3
    LeRoith D, Clemmons D, Nissley P, Rechler MM. NIH conference. Insulin-like growth factors in health and disease. Ann Intern Med 1992; 116: 85462
  • 4
    Ekman P, Lewenhaupt A. Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic information. Acta Oncologica 1991; 30: 1735
  • 5
    Rosenfeld RG, Lamson G, Pham H et al. Insulin-like growth factor-binding proteins. Recent Prog Hormone Res 1990; 46: 99163
  • 6
    Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 5636
  • 7
    Wolk A, Mantzoros CS, Andersson SO et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 9115
  • 8
    Ward AM, Cooper EH, Houghton AL. Acute phase reactant proteins in prostatic cancer. Br J Urol 1977; 49: 4118
  • 9
    Trautner K, Cooper EH, Haworth S, Ward AM. An evaluation of serum protein profiles in the long-term surveillance of prostatic cancer. Scand J Urol Nephrol 1980; 14: 1439
  • 10
    Heemskerk VH, Daemen MA, Buurman WA. Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev 1999; 10: 514
  • 11
    Cutting CW, Hunt C, Nisbet JA, Bland JM, Dalgleish AG, Kirby RS. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int 1999; 83: 9969DOI: 10.1046/j.1464-410x.1999.00088.x
  • 12
    Kurek R, Tunn UW, Eckart O, Aumuller G, Wong J, Renneberg H. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 2000; 85: 1259
  • 13
    Burgess EJ. Insulin-like growth factor 1. A valid nutritional indicator during parenteral feeding of patients suffering an acute phase response. Ann Clin Biochem 1992; 29: 13744
  • 14
    Campillo B, Paillaud E, Bories PN, Noel M, Porquet D, Le Parco JC. Serum levels of insulin-like growth factor-1 in the three months following surgery for a hip fracture in elderly: relationship with nutritional status and inflammatory reaction. Clin Nutr 2000; 19: 34954
  • 15
    McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 1998; 31: 1015

Authors

  1. Authors

Z. Latif, ARFCS(Ed), Research Fellow.

D.C. McMillan, PhD, Senior Lecturer in Surgery.

A.M. Wallace, PhD, Consultant in Biochemistry.

N. Sattar, PhD, Consultant in Biochemistry.

K. Mir, FRCS, Specialist Registrar in Urology.

G. Jones, FRCS(Urol), Specialist Registrar in Urology.

M.A. Underwood, MD, FRCS (Urol), Consultant in Urology.

Abbreviation
IGFBP-3

IGF binding protein-3